Skip to main content

Table 2 Clinicopathologic parameters of the patients and thrombocytosis

From: Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Parameters Thrombocytosis P-value
Yes No
Age <56(427) 63(14.8 %) 364(85.2 %) 0.493
≥56(447) 58(13.0 %) 389(87.0 %)
FIGO Stage Early(74) 3(4.1 %) 71(95.9 %) 0.008
Advanced(800) 118(14.8 %) 682(85.2 %)
CA125 Level <500 U/ml(193) 15(7.8 %) 178(92.2 %) 0.004
≥500 U/ml(661) 103(15.6 %) 558(84.4 %)
Hyperfibrinogenemia Yes (332) 77(23.2 %) 255(76.8 %) <0.001
No (391) 15(3.8 %) 376(96.2 %)
Ascitesa No (99) 3(3.0 %) 96(97.0 %) <0.001
<500 ml(146) 5(3.4 %) 141(96.6 %)
≥500 ml(628) 113(18.0 %) 515(82.0 %)
Cytoreductionb R0(271) 18(6.6 %) 253(93.4 %) <0.001
R1(434) 67(15.4 %) 367(84.6 %)
R2(169) 36(21.3 %) 133(78.7 %)
Chemosensitivity Yes (567) 69(12.2 %) 498(87.8 %) 0.043
No (237) 42(17.7 %) 195(82.3 %)
  1. aSubgroup analyses: PNo vs <500ml = 1.000, PNo vs >500ml < 0.001, P<500 ml vs <500ml < 0.001
  2. bSubgroup analyses: PR0 vs R1 = 0.001, PR0 vs R2 < 0.001, PR1 vs R2 = 0.092
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us